Heart failure & cardiomyopathies
Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7
Authors' conclusion
Igfbp7 produced by senescent ECs causes cardiac dysfunction and vaccine therapy targeting Igfbp7 may be useful to prevent the development of heart failure.
Study context
- Population
- Mice with pressure overload (transverse aortic constriction); tissue from HF patients
Main finding
As reported in the abstract
- Pressure overload induced intricately entwined blood vessels, with accumulation of replication stress and DNA damage in cardiac endothelial cells (ECs)
- Cyclin-dependent kinase inhibitor reduced DNA damage in ECs and ameliorated TAC-induced cardiac dysfunction
- Igfbp7 upregulated in senescent ECs; insulin signalling and oxidative phosphorylation downregulated in cardiomyocytes of murine and human failing hearts
- AAV9 overexpression of Igfbp7 exacerbated cardiac dysfunction
- EC-specific Igfbp7 deletion and vaccine targeting Igfbp7 ameliorated cardiac dysfunction with increased oxidative phosphorylation in cardiomyocytes under pressure overload
Original publication
Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7. Circulation. Published 11 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →